DeuterOncology NV

DeuterOncology NV is a clinical-stage biotechnology company based in Liege, Belgium, founded in 2020 by Dr. Timothy Perera. The company focuses on the development of DO-2, a novel, brain-penetrant, deuterated MET kinase inhibitor. By replacing metabolically labile hydrogen atoms with deuterium, the company aims to improve the metabolic stability of the molecule and overcome the tolerability issues associated with current marketed MET kinase inhibitors. The drug is designed to act as a potential best-in-class targeted therapy, showing activity on the MET kinase pathway and binding to alternative kinases within the RAS pathway.

The company's work addresses critical challenges in cancer treatment, particularly for patients with MET-altered lung cancer. Through its clinical-stage drug development efforts, DeuterOncology has conducted Phase 1 dose escalation trials across multiple sites in Belgium, the Netherlands, and France, reporting encouraging early data regarding tumor shrinkage and safety profiles. In 2026, the company was acquired as a majority stake by Pathos AI, which utilizes its Foundry platform to advance clinical development and provide data-driven insights into the therapeutic's potential. DeuterOncology collaborates with a broad network of international research partners to advance its mission of delivering optimized, personalized cancer therapies.